Appendix 3. SASB Index

▶ Biotechnology & Pharmaceuticals

Disclosure Topics	Code	Disclosure	Description	Corresponding Sections	Page
Safety of Clinical Trial Participants	HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	Clinical trials are performed in accordance with local regulatory requirements and approved trial plans. None of our clinical trials were suspended due to GCP (Good Clinical Practice) violations in 2024	3.1 New Drug Research & Development and Innovation Management	57
	HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	No associated incidents occurred in 2024	-	-
	HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	No associated incidents occurred in 2024	-	-
Access to Medicines	HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	• BESREMi is mainly used for treatment of all severities of Polycythemia Vera (PV), and is not included in the List of Prequalified Medicinal Products used for treating HIV/AIDS, malaria, tuberculosis and other diseases, and for reproductive health • However, PharmaEssentia still adhered to the Access to Medicine framework in formulating the Group's "Access to Medicine" strategy, executive plans, annual achievements, and future goals, and we implement this framework through drug license acquisitions and applications, doctor-patient interactions, and academic seminars	6.1 Access to Medicine Management	120
	HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	• Not applicable • The medicines listed on the List of Prequalified Medicinal Products are mainly used for treating HIV/AIDS, malaria, tuberculosis and other diseases, and for reproductive health. PharmaEssentia's only marketed product, BESREMi, is a long-acting interferon mainly used for treatment of all severities of Polycythemia Vera (PV), and therefore this indicator is not applicable	-	-
Affordability & Pricing	HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	Percentage changes in average list prices and average net prices for BESREMi from 2023 to 2024 were as follows: (1) List price: 8.03% (2) Net price: 4.16%	6.1 Access to Medicine Management	120
	HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year			
Drug Safety	HC-BP-250a.1	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	No associated incidents occurred in 2024	-	-
	HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	No associated incidents occurred in 2024	-	-
	HC-BP-250a.3	Number of recalls issued; total units recalled	No associated incidents occurred in 2024	3.3 Drug Safety Management and Marketing Ethics	70
	HC-BP-250a.4	Total amount of product accepted for takeback, reuse, or disposal	No associated incidents occurred in 2024	3.3 Drug Safety Management and Marketing Ethics	70
	HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	No associated incidents occurred in 2024	-	-

Disclosure Topics	Code	Disclosure	Description	Corresponding Sections	Page
Counterfeit Drugs	HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	We established a global product traceability mechanism and introduced drug serialization in accordance with the Drug Supply Chain Security Act (DSCSA), and implement drug packaging and serialization procedures to maintain drug quality and safety	3.3 Drug Safety Management and Marketing Ethics	70
	HC-BP-260a.2	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	We initiate product recall procedures for products with known or potential quality issues in accordance with the "Return and Recall Procedures" for appropriate handling of recalled products, and notify local competent authorities	3.3 Drug Safety Management and Marketing Ethics	70
	HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	No associated incidents occurred in 2024	-	-
Ethical Marketing	HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	No associated incidents occurred in 2024	3.3 Drug Safety Management and Marketing Ethics	70
	HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	The Medical, Legal, and Regulatory Affairs Review Committee conducts medical, legal, and regulatory reviews	3.3 Drug Safety Management and Marketing Ethics	70
Employee Recruitment, Development & Retention	HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	We established fair, just, diverse, and inclusive workplace environments, and set up a dual-track diverse talent development framework to cultivate management and professional talents	5.2 Diversity and Inclusion 5.4 Talent Attraction and Retention	95 107
	HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	Please refer to the corresponding section	5.2 Diversity and Inclusion	95
Supply Chain Management	HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier 1 suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	• PharmaEssentia does not currently have plans to join the Rx-360 International Pharmaceutical Supply Chain Consortium, but official agencies such as EMA and TFDA all have relevant GDP regulations to ensure supply chain management associated with drug transportation and storage, and we conduct regular audits, verifications, and certification updates • Additionally, PharmaEssentia's sustainable supply chain management procedures also ensure supplier quality and performance of other sustainability indicators. Please refer to 2.6 Sustainable Supply Chain Management	2.6 Sustainable Supply Chain Management	47
Business Ethics	HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	No associated incidents occurred in 2024	2.2 Business Integrity and Legal Compliance	36
	HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	All employees are required to abide by seven major business conduct and ethics rules, uphold principles of fairness and justice, and avoid profiting from their positions or manipulating or misusing information obtained through their roles	2.2 Business Integrity and Legal Compliance	36
Activity Metrics	HC-BP-000.A	Number of patients treated	More than 10,000 patients have been treated as of year-end 2024	-	-
	HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	(1) 1 (BESREMi) (2) 13	3.1 New Drug Research & Development and Innovation Management	57